JACN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leichtle, A.
Right arrow Articles by Thiery, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leichtle, A.
Right arrow Articles by Thiery, J.
Journal of the American College of Nutrition, Vol. 25, No. 5, 420-428 (2006)
Published by the American College of Nutrition

Alpha-Tocopherol Distribution in Lipoproteins and Anti-Inflammatory Effects Differ between CHD-Patients and Healthy Subjects

Alexander Leichtle, MD, Daniel Teupser, MD, PhD and Joachim Thiery, MD, PhD

Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, Leipzig University Hospital, Leipzig, GERMANY

Address reprint requests to: Daniel Teupser M.D., Ph.D., Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, Leipzig University Hospital, Liebigstrasse 27, 04103 Leipzig, GERMANY. E-mail: teupser{at}medizin.uni-leipzig.de

Objective: The purpose of this study was to investigate the dose-dependent effects of RRR-{alpha}-tocopherol supplementation in coronary heart disease (CHD) patients and healthy subjects on plasma {alpha}-tocopherol levels, plasma lipoprotein distribution, LDL oxidation, and inflammatory plasma markers.

Methods: 12 patients with coronary heart disease and 12 healthy subjects were supplemented with increasing dosages of RRR-{alpha}-tocopherol at 100, 200 and 400 mg/day for a period of 3 weeks per dose. Lipoproteins were separated by FPLC and ultracentrifugation. {alpha}-Tocopherol was measured by HPLC. Resistance of LDL to oxidation was determined by reading the absorption at 234 nm after CuCl2-induced oxidation. Clinical chemistry and inflammatory markers were measured on automated analysis systems.

Results: Plasma {alpha}-tocopherol concentrations at baseline were comparable between CHD-patients and healthy subjects (21.7 ± 4.7 µmol/L and 25.8 ± 7.6 µmol/L, respectively). CHD-patients showed a significant increase (59%) of plasma {alpha}-tocopherol concentrations to 34.6 ± 9.8 µmol/L at a dosage of 100 mg/day RRR-{alpha}-tocopherol, whereas healthy subjects showed a significant (54%) increase to 39.7 ± 6.1 µmol/L only with 400 mg/day RRR-{alpha}-tocopherol. In addition, CHD-patients showed a significantly increased enrichment of {alpha}-tocopherol in VLDL. Supplementation (200 mg/day) caused a significant decrease of the acute phase plasma proteins C-reactive protein (CRP) (–65%) and fibrinogen (–24%).

Conclusion: Our data demonstrate that CHD-patients require lower dosages of {alpha}-tocopherol supplementation than healthy subjects to exert biological effects on plasma lipoproteins and acute phase response.

Key words: coronary heart disease, alpha-tocopherol, vitamin E, C-reactive protein, fibrinogen






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Nutrition.